Sonja Althammer, PhD

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with nonsmall cell lung cancer (NSCLC) who respond best to treatment with the PD-L1 inhibitor durvalumab.

Findings from the analysis were presented at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs. Overall, the combination of CD8+ and PD-L1+ densities correlated with response and improved overall survival with durvalumab.

Videos

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non&ndash;small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.

Sonja Althammer, PhD | Authors

Articles

Sonja Althammer Discusses Biomarkers for Durvalumab in Lung Cancer